Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

24 juin 2021 09h30 HE | Source: Oculogica, Inc.

Oculogica’s New Patent Opens Potential for a CTE Test for Live Subjects

NEW YORK, June 24, 2021 (GLOBE NEWSWIRE) -- Oculogica, a leader in concussion diagnosis and categorization, with the only FDA-cleared technology that aids in the diagnosis of concussion without the...
25 mai 2021 10h45 HE | Source: Oculogica, Inc.

Oculogica Adds to IP Portfolio with Patent for Assessment of Impairment Due to Cannabis

NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- Oculogica, a leader in concussion diagnosis and categorization, with the only FDA-cleared technology that aids in the diagnosis of concussion without a...
18 mai 2021 09h57 HE | Source: Oculogica, Inc.

Oculogica Receives Department of Defense Grant to Develop Wearable Concussion Diagnostic with Pre-eminent Partners

NEW YORK, May 18, 2021 (GLOBE NEWSWIRE) -- Oculogica, a leader in concussion diagnosis and categorization, with the only FDA-cleared technology that aids in the diagnosis of concussion without a...
29 oct. 2019 07h45 HE | Source: Oculogica, Inc.

Oculogica Announces New Category 3 CPT Code Created by American Medical Association

NEW YORK, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Oculogica, Inc., a pioneer in algorithm-based neuro-diagnostics for brain health, announced today that the American Medical Association (AMA) has...
03 janv. 2019 07h45 HE | Source: Oculogica, Inc.

Oculogica Receives FDA Marketing Authorization for EyeBOX®, the First Non-Invasive, Baseline-Free Test for Concussion

NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Oculogica, Inc., a pioneer in algorithm-based neuro-diagnostics, announced that the U.S. Food and Drug Administration (FDA) granted their De Novo request...